ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Bristol-Myers Squibb is collaborating with the Japanese companies Nissan Chemical Industries and Teijin Pharma to develop Nissan’s NTC-801 outside Japan. Teijin already has Japanese rights. A selective inhibitor of the acetylcholine-activated potassium ion channel, NTC-801 is currently in Phase I development in Japan for treating a form of arrhythmia. BMS will pay $40 million up front and potentially make milestone payments of up to $170 million.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter